We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





Fastest Ever Robotics-Driven COVID-19 Mass Testing Platform Gives 99% Accurate Results

By LabMedica International staff writers
Posted on 01 Dec 2020
Print article
Image: Fastest Ever Robotics-Driven COVID-19 Mass Testing Platform Gives 99% Accurate Results (Photo courtesy of Salient Bio)
Image: Fastest Ever Robotics-Driven COVID-19 Mass Testing Platform Gives 99% Accurate Results (Photo courtesy of Salient Bio)
A new robotics-driven COVID-19 mass testing platform that has been rolled out is up to three times faster than competitors for mass testing and aims to provide affordable, effective and easy-to-access pre-emptive diagnostic solutions for a range of medical conditions that facilitate early intervention and improve overall health outcomes.

Salient Bio (London, UK) has announced the commercial launch of its robotics-driven COVID-19 mass testing platform which facilitates COVID-secure environments at a quicker and more cost effective rate than the closest approved competitor, with a same day results notification process and a very cost effective per unit price for businesses conducting mass testing. The platform is reagent agnostic, meaning that disruption in supply chains can be mitigated by a shift to different reagent suppliers without it calling for wholesale infrastructure change at Salient’s labs, therefore limiting disruption and costs. Its accuracy, fast delivery and cost effectiveness make Salient Bio’s modular diagnostics platform ideal for sectors that require a safe environment for regular human contact, such as logistics, facilities management, education and manufacturing.

“With the rollout of vaccines likely to be staggered, rapid and accurate mass testing will play a vital role in the coming months in our immediate fight against COVID,” said Dr. Miles Priestman, Co-founder of Salient Bio. “Yet existing diagnostic labs often involve error prone manual processes – there is a huge opportunity to reinvent how they operate from the ground up. Using state of the art robotics and bespoke software development we hope to do just this, bringing significant cost and operational efficiency gains to help bring diagnostic labs fully into the 21st century.”

Related Links:
Salient Bio


Print article

Channels

Molecular Diagnostics

view channel
Image: FIT (Fecal Immunochemical Test) is a stool test designed to identify possible signs of bowel disease. It detects minute amounts of blood in feces (fecal occult blood) (Photo courtesy of Alpha Laboratories, United Kingdom)

Study Confirms Performance of Rapid Stool Test for Detection of Colorectal Cancer

A recently published paper confirmed the diagnostic performance of the fecal immunochemical test (FIT) for patients with low-risk symptoms of colorectal cancer. The FIT uses specific antibodies to detect... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more

Industry

view channel
Illustration

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.